These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 22665983)

  • 1. Pharmacokinetic models for FcRn-mediated IgG disposition.
    Xiao JJ
    J Biomed Biotechnol; 2012; 2012():282989. PubMed ID: 22665983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human.
    Shah DK; Betts AM
    J Pharmacokinet Pharmacodyn; 2012 Feb; 39(1):67-86. PubMed ID: 22143261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incorporation of FcRn-mediated disposition model to describe the population pharmacokinetics of therapeutic monoclonal IgG antibody in clinical patients.
    Ng CM
    Biopharm Drug Dispos; 2016 Mar; 37(2):107-19. PubMed ID: 26581439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Model-Based Assessment of the Contribution of Monocytes and Macrophages to the Pharmacokinetics of Monoclonal Antibodies.
    Malik PRV; Hamadeh A; Edginton AN
    Pharm Res; 2022 Feb; 39(2):239-250. PubMed ID: 35118567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice.
    Garg A; Balthasar JP
    J Pharmacokinet Pharmacodyn; 2007 Oct; 34(5):687-709. PubMed ID: 17636457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the FcRn developmental pharmacology on the pharmacokinetics of therapeutic monoclonal IgG antibody in pediatric subjects using minimal physiologically-based pharmacokinetic modelling.
    Hardiansyah D; Ng CM
    MAbs; 2018 Oct; 10(7):1144-1156. PubMed ID: 29969360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics.
    Piche-Nicholas NM; Avery LB; King AC; Kavosi M; Wang M; O'Hara DM; Tchistiakova L; Katragadda M
    MAbs; 2018 Jan; 10(1):81-94. PubMed ID: 28991504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity?
    Gurbaxani B; Dostalek M; Gardner I
    Mol Immunol; 2013 Dec; 56(4):660-74. PubMed ID: 23917469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In Translation: FcRn across the Therapeutic Spectrum.
    Qi T; Cao Y
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanistic incorporation of FcRn binding in plasma and endosomes in a whole body PBPK model for large molecules.
    de Witte WEA; Avery LB; Mackness BC; Van Bogaert T; Park A; Sargentini-Maier ML
    J Pharmacokinet Pharmacodyn; 2023 Jun; 50(3):229-241. PubMed ID: 36877385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of a catenary PBPK model for predicting the in vivo disposition of mAbs engineered for high-affinity binding to FcRn.
    Chen Y; Balthasar JP
    AAPS J; 2012 Dec; 14(4):850-9. PubMed ID: 22956476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences.
    Wang W; Lu P; Fang Y; Hamuro L; Pittman T; Carr B; Hochman J; Prueksaritanont T
    Drug Metab Dispos; 2011 Sep; 39(9):1469-77. PubMed ID: 21610128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetics of FcRn-mediated recycling of IgG and albumin in human: pathophysiology and therapeutic implications using a simplified mechanism-based model.
    Kim J; Hayton WL; Robinson JM; Anderson CL
    Clin Immunol; 2007 Feb; 122(2):146-55. PubMed ID: 17046328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minimal physiologically-based pharmacokinetic model to investigate the effect of pH dependent FcRn affinity and the endothelial endocytosis on the pharmacokinetics of anti-VEGF humanized IgG1 antibody in cynomolgus monkey.
    Hardiansyah D; Ng CM
    Eur J Pharm Sci; 2018 Dec; 125():130-141. PubMed ID: 30248389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the interactions of rabbit neonatal Fc receptor (FcRn) with rabbit and human IgG isotypes.
    Szikora B; Hiripi L; Bender B; Kacskovics I; Iliás A
    PLoS One; 2017; 12(9):e0185662. PubMed ID: 28957416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Albumin binding to FcRn: distinct from the FcRn-IgG interaction.
    Chaudhury C; Brooks CL; Carter DC; Robinson JM; Anderson CL
    Biochemistry; 2006 Apr; 45(15):4983-90. PubMed ID: 16605266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of Physiologically Based Pharmacokinetic Modeling to Predict the Effects of FcRn Inhibitors in Mice, Rats, and Monkeys.
    Li T; Balthasar JP
    J Pharm Sci; 2019 Jan; 108(1):701-713. PubMed ID: 30423340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life.
    Souders CA; Nelson SC; Wang Y; Crowley AR; Klempner MS; Thomas W
    MAbs; 2015; 7(5):912-21. PubMed ID: 26018774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parameter Identification for a Model of Neonatal Fc Receptor-Mediated Recycling of Endogenous Immunoglobulin G in Humans.
    Kendrick F; Evans ND; Berlanga O; Harding SJ; Chappell MJ
    Front Immunol; 2019; 10():674. PubMed ID: 31024535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contribution of FcRn binding to intestinal uptake of IgG in suckling rat pups and human FcRn-transgenic mice.
    Kliwinski C; Cooper PR; Perkinson R; Mabus JR; Tam SH; Wilkinson TM; Giles-Komar J; Scallon B; Powers GD; Hornby PJ
    Am J Physiol Gastrointest Liver Physiol; 2013 Feb; 304(3):G262-70. PubMed ID: 23220220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.